The resulting conditionally activated small-molecule drug conjugates (CA-SMDCs) selectively deliver their therapeutic payloads to tumor cells as well as to TIME-associated immunosuppressive cells ...
The Werewolf technology uses design elements that address pharmaceutical, potency and tissue selectivity properties, previously a challenge for conditionally activated agents. Werewolf completed ...